Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...

CNBC’s Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results. Make some room on ...

The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...

Studies show psilocybin from mushrooms could revolutionize depression treatment offering hope to millions who don't respond to traditional medications.

Those on the extreme end of the depression spectrum face symptoms that impact their daily activities too and not just their ...

Ketamine, a hallucinogenic drug approved as an anesthetic, has been used to treat adults with depression, PTSD and other conditions, and studied in youth with depression.

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

Jan 2 (Reuters) - Neumora Therapeutics' (NMRA.O), opens new tab shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and ...

How Can Low-Dose Ketamine, a 'Lifesaving' Drug for Major Depression, Alleviate Symptoms Within Hours? Nov. 18, 2024 — Neuroscientists have identified the binding site of low-dose ketamine ...